Fig. 6.

G6PD activity inhibition attenuated the growth of ccRCC cells both in vitro and in vivo. a 786-O cells were treated with 6-AN at indicated doses for 24 h, and reduced G6PD activities were verified using a G6PD Assay Kit. b After treating 786-O cells with 6-AN at indicated doses for 12, 24, 36 or 48 h, the relative proliferative rate was analyzed by MTS assay. c 786-O parental tumor-bearing nude mice were treated with vehicle or 6-AN for 2 weeks. Representative images of tumor-bearing mice (top panel) and tumors isolated from each group (bottom panel) are shown. d Tumor volumes were measured at the indicated days. e The average tumor weights were calculated after euthanasia and tumor harvesting. Western blot analysis (f) and grayscale scanning (g) for detecting G6PD, pSTAT3, and p65 levels in the whole-cell lysates of two random tumor samples. GAPDH levels served as loading controls. Each bar represents the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 vs control or vehicle